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The aggregation of platelets induced by soluble and particulate stimuli is enhanced by the addition of minute 
amounts of HZOZ. Externally added catalase strongly inhibits the aggregation induced by particulate stimuli 
and by phorboi myristate acetate (PMA). The addition of aminotriazole to stimulated platelets causes a 
significant inhibition of intracellular catalase. This indicates the formation of H,O, inside the platelets dur- 
ing activation. No effects were observed when the platelets were stimulated by the ionophore A23 187. 
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1, INTRODUCTION 
The interaction of Hz02 with platelets in vitro 
has been extensively studied because it is thought 
that ptatelets can be exposed in vivo to the Hz02 
produced by PMN cells undergoing the respiratory 
burst [l]. However, the reports on the interaction 
of platelets with Hz02 appear to be conflicting. In 
fact, some authors found that Hz02 is a powerful 
inhibitor of platelet functions 12,3] while others 
found that Hz02 may induce aggregation of 
platelets [4]. Moreover, the aggregation is in- 
hibited by a variety of antioxidants and scavengers 
of Hz02 [5-g]. Yoshikawa et al. [9] recently 
reported that catalase can prevent he intravascular 
coagulation in rats induced by endotoxin. It has 
also been reported that Hz02 alone or in the 
presence of myeloperoxidase stimulates various 
platelet activities, such as the hexose monophos- 
phate shunt 14, IO], and that platelets may consume 
Abbrevzotjo~s: AT, 3-amino-1,2,4-triazole; PMA, phor- 
bol myristate acetate; U46619,15(S)-hydroxy-9a, 11~ 
methanoepoxyprostadienoic acid; PMN, polymorpho- 
nuclear cell; PBS, phosphate-buffered saline 
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large amounts of Hz02 added to the incubation 
medium [I 11. These reports together with growing 
evidence that the generation of Hz02 by cells is in- 
deed purposeful and can no longer be considered 
as a mere undesirable byproduct of cell respiration 
[12] prompted us to investigate in more detail the 
role of Hz02 in platelets. We previously reported 
that platelets carry a membrane-bound H202- 
generating system which is activated by immuno- 
logical stimuli [ 131. In fact human platelets have 
been shown to release minute amounts of Hz02 
after stimulation with latex or opsonized zymosan 
1141. 
Here we report that externally added catalase 
causes inhibition of platelet aggregation induced 
by several different stimuli. Moreover, almost all 
the platelet agonists investigated o induce Hz02 
generation inside the platelets. 
2. MATERIALS AND METHODS 
The chemicals were from commercial sources 
and were used without further purification. Plate- 
lets were prepared from blood samples obtained 
from healthy donors not taking any drugs for at 
least 20 days, after informed consent. Blood, col- 
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lected in 3.8% Na citrate or 5 mM EDTA, was cen- 
trifuged at 1OOxg for 15 min. Residual PMNs 
were eliminated by centrifuging the plasma through 
a Ficoll layer (23070, w/v) at 80 x g for 20 min. This 
procedure gave the PRP used for the aggregation 
studies. A further centrifugation of PRP at 1200 X g 
for 15 min gave a platelet-containing pellet and a 
supernatant platelet-free plasma. The pellet was 
resuspended in Dulbecco’s PBS, pH 7.4, at a con- 
centration of 3.3 x 10’ platelets/ml. These platelet 
preparations contained less than 1 PMN/lO’ cells 
[14,15]. Platelets were activated with agonists and 
with opsonized zymosan as described [ 141. Activa- 
tion experiments were performed at least in tripli- 
cate in the presence and absence of crystalline 
bovine liver catalase (Sigma, St. Louis). Further 
controls with catalase inactivated by heat or by 
treatment with AT (Fluka AG, Switzerland) and 
peroxide [16] were also carried out. Platelet ag- 
gregation was monitored by the change in light 
transmission at 650 nm in a model 840 dual- 
channel Elvi aggregometer (Elvi Logos, Milan) ac- 
cording to Born [ 171. Platelet catalase activity in 
the presence and absence of 1 mM AT was 
measured at 3O”C, using an oxygen-sensitive elec- 
trode (Yellow Springs Instruments, OH) in a 3 ml 
vessel. The enzymic activity was measured in lysed 
platelet suspensions. At the end of incubation with 
agonists, the reaction was stopped with melting 
ice. After accurate removal of AT by at least 3 
washings, the platelets were disrupted by homo- 
genization in a teflon potter. The sample (200 ~1) 
was diluted in the oxygraph vessel with 2 ml dis- 
tilled water. When thermal equilibrium was 
reached, Hz02 was acded to a final concentration 
of 8 mM, and catalase-catalyzed Hz02 degradation 
was recorded. The spontaneous degradation of 
Hz02 was also recorded and subtracted according- 
ly from the oxygen production in the presence of 
catalase. Specific activity of catalase was defined 
as nmol 02 generated/min per mg platelet protein 
[181. Peroxidase activity was determined 
spectrophotometrically in the presence of 10 mM 
Hz02 and o-dianisidine as in [ 191. Protein was 
determined by the method of Lowry et al. [20]. 
3. RESULTS 
The addition of catalase to a platelet suspension 
strongly reduced the extent of aggregation induced 
by particulate stimuli (latex particles, opsonized 
zymosan, collagen) (fig. 1 A-C) or by a membrane- 
perturbing agent such as PMA (fig.lD). Boiled 
catalase or catalse inactivated by AT and peroxide 
was without effect. The aggregation induced by 
soluble stimuli (ADP, thrombin, epinephrine) was 
instead insensitive to the presence of catalase 
(fig.lE-G). However, this enzyme strongly in- 
hibited the ADP-induced aggregation of platelets 
from a patient bearing Kawasaki’s disease (fig.2A). 
This effect was only observed during the acute 
phase of the disease, when a hyperaggregability of 
platelets was also present. In the remission stage, 
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Fig. 1. Effect of catalase and Hz02 on platelet aggrega- 
tion. (A) Aggregation of PRP induced by collagen (2 
pg/ml). a, no addition; b, + catalase; c, + H202. (B) 
Aggregation of PRP induced by latex (0 0.08 pm, 100 
particles/platelet. a, no addition; b, + catalase; c, + 
H202. (C) Aggregation of PRP induced by zymosan (4 
mg/ml). a, opsonized zymosan alone; b, opsonized 
zymosan + catalase; c, opsonized zymosan + H202; d, 
non-opsonized zymosan; e, non-opsonized zymosan + 
H202. (D) Aggregation of PRP induced by PMA (20 nM 
final concentration). a, no addition; b, + catalase. (E) 
Aggregation of PRP induced by ADP (1 pM). a, no ad- 
dition; b, + catalase; c, + HzOZ. (F) Aggregation of 
PRP induced by epinephrine (0.5rM). a, no addition; b, 
+ catalase. (G) Aggregation of a platelet suspension in 
Dulbecco’s PBS (109/ml) induced by cu-thrombin (0.05 
U). a, no addition; b, + catalase; c, + H202. Where 
added catalase was 500 U;H202 was 200 nM. 
143 
Volume 18.5, number 1 FEBS LETTERS June 1985 
Table 1 
Catalase activity of platelets 
Experiments -AT +-AT (1 mM) 
(mean ? SE) (mean k SE) n 
t’“~_, ; 
1 3 5 
tlme(mm) 
Fig.2. Aggregation of PRP from a patient with 
Kawasaki’s disease. (A) During the acute phase. a, ADP 
(1 FM); b, + ADP and catalase. (B) During the remis- 
sion phase. a, ADP (1 PM); b, + ADP and catalase. The 
patient was a 4-year-old girl (E.D.), who presented 6 out 
of the 6 symptoms of Kawasaki’s disease [21]. The rever- 
sibility of aggregation is due to the fact that the patient 
was under treatment with acetylsalicylic acid. 
catalase no longer affected ADP-induced aggrega- 
tion, as found in healthy subjects (fig.2B). It is im- 
portant to note that at this stage the patient also 
did not show platelet hyperaggregability. Non- 
opsonized zymosan is unable to elicit the aggrega- 
tion of platelets except in the presence of 200 nM 
HzOz. The addition of peroxide also increased the 
aggregation induced by collagen, and to a lesser ex- 
tent, that induced by ADP and thrombin. The ag- 
gregation induced by A23187 was not affected by 
the addition of catalase, while it was inhibited by 
exogenous H202. 
Further evidence of the involvement of Hz02 in 
the aggregation process was obtained by poisoning 
the platelets with AT. This compound forms an ir- 
reversible adduct with catalase only in the presence 
of Hz02 [16]. The incubation of platelets with 1 
mM AT and 1 mM Hz02 for 15 min produced 50% 
inhibition of the intracellular catalase. Greater in- 
hibition of catalase was obtained when platelets 
were incubated with AT aIone and then stimulated 
with collagen, ADP, opsonized zymosan, PMA, 
U46619, and low amounts (0.05 U/mi) of throm- 
bin (table 1). Larger amounts (22 U/ml) of 
thrombin and A23187 did not produce significant 
inactivation of platelet cataIase. The activity of 
peroxidase was only slightIy affected by AT. 
Resting platelets 
Stimulated platelets 
+ A23187 
-c U46619 
i latex 
+ collagen 
+ PMA 
+ ADP (1 PM) 
+ ADP (0.2,~M) 
+ thrombin 
(0.05 U/ml) 
3.70+ 0.25 
3.60 3.1 3 
3.60 1.5 3 
3.75kO.15 1.5 to.25 6 
3.5o-to.15 1.0 kO.25 8 
3.6OkO.26 1.2 k-o.12 6 
3.0 1.4 3 
3.50 1.0 3 
3.0 1.3 3 
3.20+-0.8 7 
Values expressed as nmol 02 producedimg protein 
4. DISCUSSION 
A recent review [12] has put into focus the 
widespread generation of Hz02 in cellular plasma 
membranes and its role in several cellular phenom- 
ena. Moreover, the production of Hz02 in 
mitochondria, microsomes, peroxisomes and 
nuclei is well estabIished 1121. 
We have reported that platelets do release small 
amounts of Hz02 when challenged with par- 
ticulate, immunological stimuli [ 141. Here, we fur- 
ther show that the presence of externally added ac- 
tive catalase strongly decreases the aggregation of 
platelets triggered by particulate stimuli and by 
membrane-perturbing agents such as PMA. Solu- 
ble stimuli do not cause a detectable release of 
Hz02 from platelets. Accordingly, the aggregation 
of normal human platelets induced by these agents 
is not affected by the presence of cataiase. One in- 
teresting exception is presented by the platelets 
drawn from a girl affected by the Kawasaki’s 
disease [21]. During the acute phase of the disease, 
the aggregation induced by ADP was dramatically 
decreased by catalase. This effect was not seen to 
increase during the recovery period, when the 
platelets no longer showed hyperaggregability as in 
the acute phase. 
The addition of minute amounts of Hz02 to a 
platelet suspension to some extent enhanced the 
aggregation induced by most stimuli (fig.1). The 
most spectacular effect of Hz02 was observed with 
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non-opsonized zymosan, which was unable to trig- 
ger the aggregation except in the presence of Hz02 
as was the peroxide alone. 
The experiments with AT clearly demonstrated 
that Hz02 is produced in the course of platelet ac- 
tivation with all stimuli used except the ionophore 
A23187 (table 1). Conversely, Hz02 was inhibitory 
with this stimulus only. This finding may suggest 
either that there is more than one mechanism of 
platelet activation, or that the production of Hz02 
is an intermediate in a cascade process, perhaps oc- 
curring after the formation of arachidonic acid 
products but before the mobilization of Ca2+. The 
latter hypothesis seems to be substantiated by the 
formation of HZOZ induced by the stable analogue 
of prostaglandin endoperoxides U46619, and by 
the experiments done with A23187. However, the 
differential sensitivity of platelets to external 
catalase depending on the type of stimulus (soluble 
or particulate) used seems to indicate that different 
transduction mechanisms of the external stimuli 
might be operating. Nishizuka [22] in fact sug- 
gested that the information can be brought inside 
from the platelet surface after the binding of a 
stimulatory agent either by the activation of pro- 
tein kinase or by calcium mobilization [22]. The 
presence of alternative routes may allow finer con- 
trol over different processes in the same cell. We 
suggest hat Hz02 plays a role in such transduc- 
tion. Similarly, Hz02 was found to mimick the in- 
sulin effect on adipocytes and to stimulate the lym- 
phocyte blastization [23,24]. A relationship be- 
tween oxidative agents and hypercoagulability has 
been suggested [25,26]. Furthermore, several ines 
of evidence have established a clear correlation 
between Hz02 and Ca*+ flux in mitochondria, 
microsomal vescicles and plasma membranes 
[27-291. A physiological relevance of the peroxide- 
induced release of Ca2+ has been proposed [30]. 
It is conceivable that the level of H202 produced 
upon stimulation may vary as a function of 
physiological or pathological states of the platelets, 
Further study is required to ascertain whether the 
production of Hz02 is impaired when the ag- 
gregability of platelets is altered as in Kawasaki’s 
disease, and to investigate the possible use of 
catalase as an anti-aggregating agent in vivo 191. 
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